U.S. markets close in 5 hours
  • S&P 500

    +74.11 (+1.62%)
  • Dow 30

    +434.87 (+1.26%)
  • Nasdaq

    +236.68 (+1.52%)
  • Russell 2000

    +40.53 (+1.84%)
  • Crude Oil

    +2.20 (+3.32%)
  • Gold

    +12.30 (+0.69%)
  • Silver

    -0.13 (-0.57%)

    -0.0001 (-0.01%)
  • 10-Yr Bond

    +0.0460 (+3.19%)

    +0.0012 (+0.09%)

    -0.1910 (-0.17%)

    +981.81 (+1.70%)
  • CMC Crypto 200

    +26.07 (+1.77%)
  • FTSE 100

    +83.99 (+1.19%)
  • Nikkei 225

    +113.86 (+0.41%)

Those who invested in Amicus Therapeutics (NASDAQ:FOLD) five years ago are up 43%

  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

When you buy and hold a stock for the long term, you definitely want it to provide a positive return. Better yet, you'd like to see the share price move up more than the market average. But Amicus Therapeutics, Inc. (NASDAQ:FOLD) has fallen short of that second goal, with a share price rise of 43% over five years, which is below the market return. Unfortunately the share price is down 20% in the last year.

Let's take a look at the underlying fundamentals over the longer term, and see if they've been consistent with shareholders returns.

Check out our latest analysis for Amicus Therapeutics

Amicus Therapeutics isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. When a company doesn't make profits, we'd generally expect to see good revenue growth. Some companies are willing to postpone profitability to grow revenue faster, but in that case one does expect good top-line growth.

In the last 5 years Amicus Therapeutics saw its revenue grow at 54% per year. That's well above most pre-profit companies. While long-term shareholders have made money, the 7% per year gain over five years fall short of the market return. You could argue the market is still pretty skeptical, given the growing revenues. It could be that the stock was previously over-priced - but if you're looking for underappreciated growth stocks, these numbers indicate that there might be an opportunity here.

The company's revenue and earnings (over time) are depicted in the image below (click to see the exact numbers).


We like that insiders have been buying shares in the last twelve months. Even so, future earnings will be far more important to whether current shareholders make money. So it makes a lot of sense to check out what analysts think Amicus Therapeutics will earn in the future (free profit forecasts).

A Different Perspective

While the broader market gained around 36% in the last year, Amicus Therapeutics shareholders lost 20%. However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period. Longer term investors wouldn't be so upset, since they would have made 7%, each year, over five years. It could be that the recent sell-off is an opportunity, so it may be worth checking the fundamental data for signs of a long term growth trend. It's always interesting to track share price performance over the longer term. But to understand Amicus Therapeutics better, we need to consider many other factors. Consider for instance, the ever-present spectre of investment risk. We've identified 1 warning sign with Amicus Therapeutics , and understanding them should be part of your investment process.

Amicus Therapeutics is not the only stock that insiders are buying. For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.